● Business WireNov 16, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced it has entered into a definitive agreement to acquire Ollin Biosciences, Inc., (“Ollin”) a clinical-stage biopharmaceutical company deve…
● Defense WorldNov 14, 2026 · 04:41 ETEARNINGS EXPECTED BY JAN 25
Johnson & Johnson $JNJ Shares Newly Purchased by AlpenGlobal Capital LLC
AlpenGlobal Capital LLC acquired a new stake in Johnson and Johnson (NYSE: JNJ) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acq…
● Defense WorldNov 13, 2026 · 03:57 ETEARNINGS EXPECTED BY JAN 25
2,825 Johnson & Johnson $JNJ Shares Sold by Barr E S & Co.
Barr E S and Co. lessened its position in Johnson and Johnson (NYSE: JNJ) by 2.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fun…
Amid the broader tech sell-off following Nvidia (NVDA) CEO Jensen Huang's resignation, Dan Deming looks to healthcare and “anti-AI” plays for stability. He says he's following the momentum in stocks including Johnson & J…
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ
NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson ("J&J" or the "Company") (NYSE: JNJ). Such investors are advised to contact Danielle Peyton at ne…
Johnson & Johnson vs. Eli Lilly: Which Healthcare Giant's Stock Is a Better Buy for 2027?
Johnson & Johnson maintains a massive healthcare presence across both innovative medicines and advanced medical technologies. Eli Lilly is currently defined by explosive growth in the metabolic health market, particularl…
Massachusetts Woman's Family Awarded $3.3 Million Against Johnson & Johnson in Mesothelioma Case
DALLAS--(BUSINESS WIRE)--National plaintiffs trial firm Dean Omar Branham Shirley, LLP, (DOBS) has secured a verdict in the amount of $1,914,990 accompanied by court ordered interest of $1,410,541 for a sum total of $3,3…
SGOV Yields 3.63%. Can Johnson & Johnson or Verizon Pay Retirees More?
One income stream resets every time the Fed moves, while two others depend on a board's vote and a balance sheet. Which payout holds up best over a long retirement, and why might taxes change the answer?…
Dean Omar Branham Shirley Secures $3,325,000 Verdict Against Johnson & Johnson in Mesothelioma Case
DALLAS--(BUSINESS WIRE)--National plaintiffs trial firm Dean Omar Branham Shirley, LLP, (DOBS) has secured a $3,325,000 jury verdict against Johnson & Johnson on behalf of the family of Winifred “Missy” Haddad, a Massach…
● PRNewsWireNov 10, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Johnson & Johnson Announces CAPLYTA (lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Second Pivotal Phase 3 Study
CAPLYTA improved manic symptoms versus placebo as early as Day 3, with improvement sustained through Week 3 and a safety and tolerability profile consistent with prior studies Two positive Phase 3 studies will support a …
● PRNewsWireNov 8, 2026 · 11:00 ETCOMPANY'S OWN WORDS
Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer
First-of-its-kind dual-antigen-targeted bispecific regimen of pasritamig and JNJ-9401 directed at two prostate cancer proteins, KLK2 and PSMA, using complementary signals to activate T cells against cancer Deep and susta…
● PRNewsWireNov 7, 2026 · 10:03 ETCOMPANY'S OWN WORDS
Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide
Late-breaking data from Phase 3 investigational study presented at the American College of Rheumatology Convergence show 58% of ICOTYDE-treated patients achieved an ACR20 response and 29% achieved an ACR50 response at We…
● PRNewsWireNov 7, 2026 · 10:03 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY JAN 25
Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients
New patient experience data a to be presented at ACR 2026 show mouth dryness was reported as the most important symptom to improve, followed by eye dryness, fatigue and joint pain Patient insights complement Phase 2 stud…
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ
NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson ("J&J" or the "Company") (NYSE: JNJ). Such investors are advised to contact Danielle Peyton at newa…
Article counts from the last market-wide feed page, across every symbol we track and not just JNJ · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.
The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.